烟酰乙酸甲酯 | 54950-20-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 烟酰乙酸甲酯
• 中文别名: 3-氧代-3-吡啶-3-基丙酸甲酯
• 英文名称: methyl nicotinoylacetate
• 英文别名: methyl 2-(nicotinoyl)acetate；methyl 3-oxo-3-(pyridine-3-yl)propanoate；methyl 3-keto-3-(3'-pyridyl)-propionate；methyl 3-oxo-3-(pyridin-3-yl)propanoate；methyl 3-keto-3-(3'-pyridyl)propionate；methyl 3-oxo-3-(3-pyridinyl)propanoate；methyl 3-oxo-3-pyridin-3-ylpropanoate
• CAS: 54950-20-8
• 化学式: C₉H₉NO₃
• 分子量: 179.175
• InChiKey: JUQKVXRLRKKRPL-UHFFFAOYSA-N

物化性质

• 熔点：
  34-42 °C
• 沸点：
  128-129 °C(Press: 1 Torr)
• 密度：
  1.189±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2933399090
• 储存条件：
  存于2至8℃阴凉干燥处密封保存。

SDS

Name:	Methyl nicotinoylacetate Material Safety Data Sheet
Synonym:	None
CAS:	54950-20-8

Section 1 - Chemical Product MSDS Name:Methyl nicotinoylacetate Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
54950-20-8	Methylnicotinoyl acetate	100.0	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
Ingestion of large amounts may cause gastrointestinal irritation.
Inhalation:
May cause respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Antidote: None reported.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray or dry chemical.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Good general ventilation should be sufficient to control airborne levels. Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Exposure Limits CAS# 54950-20-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Negligible
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 39 - 42 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water: neglegible in water
Specific Gravity/Density:
Molecular Formula:
Molecular Weight: 179.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
High temperatures.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 54950-20-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methylnicotinoyl acetate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 54950-20-8: No information available.
Canada
CAS# 54950-20-8 is listed on Canada's NDSL List.
CAS# 54950-20-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 54950-20-8 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  烟酰乙酸甲酯 在 盐酸 、 N,N-二甲基甲酰胺 作用下， 生成 麦司明
  参考文献：
  名称：

  New Syntheses of Myosmine

  摘要：

  DOI：

  10.1021/ja01558a041
• 作为产物：
  描述：

  (Z)-2-Methoxycarbonyl-1-pyridin-3-yl-ethenol anion 在 盐酸 作用下， 以 水 为溶剂， 生成 烟酰乙酸甲酯
  参考文献：
  名称：

  Bunting, John W.; Kanter, James P., Journal of the American Chemical Society, 1993, vol. 115, # 25, p. 11705 - 11715

  摘要：

  DOI：

文献信息

• Synthesis of Functionalized Imidazolium Salts via Iodine-Mediated Annulations of Enamines
  作者：Biao Xia、Wenjun Chen、Qiongli Zhao、Wenquan Yu、Junbiao Chang

  DOI：10.1021/acs.orglett.9b00541

  日期：2019.4.19

  A novel annulation reaction of two enamine molecules with iodine under basic conditions to form 4-functionalized imidazolium salts has been established. In this reaction, iodine acts as both an iodinating reagent and a Lewis acid catalyst. Features of this synthetic method include facilitative preparation of substrates, no use of transition metals, mild reaction conditions, simplicity of operation

  建立了在碱性条件下两个烯胺分子与碘的新型环化反应，形成4-官能化的咪唑鎓盐。在该反应中，碘既充当碘化试剂又充当路易斯酸催化剂。这种合成方法的特点包括便于制备底物，不使用过渡金属，温和的反应条件，操作简便和克级合成。
• [EN] AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF<br/>[FR] AZAINDAZOLES COMME MODULATEURS DE LA KINASE BTK ET LEUR UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011019780A1

  公开（公告）日：2011-02-17

  Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A1, A2, A3, R4, are as defined herein.

  具有化学式(I)的化合物，以及其对映体、非对映异构体、药用可接受的盐，(I)可用作激酶调节剂，包括Btk调节，在此处定义了A1、A2、A3、R4。
• Facile synthesis of 1,2,3-tricarbonyls from 1,3-dicarbonyls mediated by cerium(IV) ammonium nitrate
  作者：Akhil Sivan、Ani Deepthi

  DOI：10.1016/j.tetlet.2014.01.145

  日期：2014.3

  A mild and efficient protocol for the synthesis of vicinal tricarbonyl compounds from β-dicarbonyls in a single step using cerium(IV) ammonium nitrate as a catalytic oxidant is described. Ease of execution, wide substrate scope and the suitability for the synthesis of commercially important compounds like ninhydrin, alloxan and oxoline make this reaction particularly noteworthy.

  描述了一个温和而有效的方案，该步骤使用硝酸铈（IV）铵作为催化氧化剂，一步一步从β-二羰基合成邻位三羰基化合物。易于实施，广泛的底物范围以及对合成重要的化合物（如茚三酮，四氧六环和氧杂环丁烷）的适用性使该反应特别引人注目。
• Synthesis and muscarinic activities of 3-(pyrazolyl)-1,2,5,6-tetrahydropyridine derivatives
  作者：Ralf Plate、Marc J.M. Plaum、Thijs de Boer、John S. Andrews、Duncan R. Rae、Sam Gibson

  DOI：10.1016/0968-0896(96)00001-6

  日期：1996.2

  A series of 3-(pyrazolyl)-1,2,5,6-tetrahydropyridine derivatives (B) was synthesized and tested for muscarinic activity in receptor binding assays using [3H]-oxotremorine-M (3H-OXO-M) and [3H]-pirenzepine (3H-PZ) as ligands. Potential muscarinic agonistic or antagonistic properties of the compounds were determined using binding studies measuring their potencies to inhibit the binding of 3H-OXO-M and

  合成了一系列3-（吡唑基）-1,2,5,6-四氢吡啶衍生物（B），并使用[3H]-氧代remorine-M（3H-OXO-M）和[[H] 3 H]-哌仑西平（3H-PZ）作为配体。使用结合研究确定化合物的潜在毒蕈碱激动或拮抗特性，所述结合研究测量其抑制3H-OXO-M和3H-PZ结合的能力。优先抑制3H-OXO-M的结合作为潜在毒蕈碱激动特性的指标。在隔离器官的功能研究中证实了这种潜力。所有具有激动特性的化合物均显示3H-PZ / 3H-OXO-M效能比超过20。相反，对于拮抗剂，发现该比值接近于1。单卤化产生的化合物（4b和4d）具有M3激动特性，如豚鼠回肠中对阿托品敏感的刺激特性所示，但M1活性很小或没有。两种化合物均观察到一些轻微的体内作用，碘化化合物4d诱导唾液分泌。化合物4d在大鼠中还显示出一些积极的记忆特性，其中暂时的胆碱能耗竭损害了空间短期记忆。这些数据表明在旨在治疗阿尔茨海
• Substituted indoles and their use as integrin antagonists
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020169200A1

  公开（公告）日：2002-11-14

  The present invention relates to novel substituted indole compounds that are antagonists of alpha V (&agr;v) integrins, for example &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: 1 where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , D, X, W, a, m, n, i, j, k and v are defined herein.

  本发明涉及新型取代吲哚化合物，其为αV（αv）整合素的拮抗剂，例如αvβ3和αvβ5整合素，其药学上可接受的盐以及其药物组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理性状况，包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病视网膜病变和类风湿性关节炎等病症。这些化合物具有以下一般式： 1 其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、D、X、W、a、m、n、i、j、k和v在此处定义。